Neuropace (NASDAQ: NPCE) revenue
Neuropace reported revenue of $100.0m for fiscal 2025, 25.1% more than in fiscal 2024 ($79.9m). Since fiscal 2020 its revenue has grown by 143.1%, an average growth of 19.4% a year.
Neuropace has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $100.0m | +25.1% | −$16.3m | −16.3% |
| 2024 | $79.9m | +22.1% | −$21.7m | −27.1% |
| 2023 | $65.4m | +43.7% | −$27.2m | −41.5% |
| 2022 | $45.5m | +0.7% | −$40.8m | −89.6% |
| 2021 | $45.2m | +9.8% | −$23.7m | −52.5% |
| 2020 | $41.1m | — | −$13.1m | −31.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Neuropace revenue compared with its sector
By revenue for its latest fiscal year, Neuropace ranks 287th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Neuropace, 25.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 285th | Sutro Biopharma | $102.5m | 65.2% |
| 286th | Beta Bionics | $100.3m | 53.9% |
| 287th | Neuropace | $100.0m | 25.1% |
| 288th | Butterfly Network | $97.6m | 19.0% |
| 289th | BioLife Solutions | $96.2m | 28.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Neuropace
- How much revenue did Neuropace make in fiscal 2025?
- Neuropace reported revenue of $100.0m for fiscal 2025, compared with $79.9m in fiscal 2024.
- How much has the revenue of Neuropace grown?
- Between fiscal 2020 and fiscal 2025 it went from $41.1m to $100.0m: 143.1% more, an average growth of 19.4% a year.
- What was the best year for revenue at Neuropace?
- Of its last 6 fiscal years, fiscal 2025, with $100.0m.
- Where does Neuropace rank in its sector by revenue?
- It ranks 287th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Neuropace come from?
- From the annual report (Form 10-K) that Neuropace files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Neuropace files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Neuropace: the Neuropace page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.